← Leaderboards
Daniel Addison
Ohio State University
$3,345,439
Attributed
$4,811,895
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2021–25$2.5M$1.9M$1.3M$625K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,811,895 · 4
By mechanism
R01$4,149,207 · 3
K23$662,688 · 1
Top collaborators
- Sharyn D Baker2 shared
- Alexander Sparreboom2 shared
- Weidan Cao1 shared
- Dakuo Wang1 shared
- Ping Zhang1 shared
Most similar at Ohio State University
Same institution · by research overlap
- Ann Scheck McAlearney$8,849,739
- Sharyn D Baker$10,060,478
- Kimerly Ann Powell$868,726
- Donna F Kusewitt$2,059,082
- Soledad A Fernandez$6,328,596
Others in their field
Other Emerging Leaders on “Cardiotoxicity”
- Richard Scranton · Lyndra Therapeutics, Inc.$9,277,094
- Nicholas Andrew Geisse · Curi Bio Inc$6,427,007
- Vera Hoffman · Reveal Pharma$6,279,676
- Patrick Boen · Lyndra Therapeutics, Inc.$5,849,897
- Zhongxing Liao · University Of Tx Md Anderson Can Ctr$4,193,578
- Suchismita Acharya · Ayuvis Research, Inc.$4,173,619
Research focus
CardiotoxicityEventInsightCardiacPathway InteractionsIncidencePharmaceutical PreparationsOncologyLeadAffectArrhythmiaCardiac Magnetic Resonance ImagingLinkAnimalsAnimal ModelAnimal DataAdultCancer PatientChronic Lymphocytic LeukemiaHeart AtriumCohortBlood VesselsHypertensionAgammaglobulinaemia Tyrosine Kinase
Grant awards (10)
Therapeutic Strategies to Mitigate Toxicities of Anthracycline-Based Therapeutics$746,337
R01 · FY2025 · HL
Novel patient biomarkers and mechanisms of TKI associated Cardiotoxicity$703,582
R01 · FY2025 · HL · contact PI
Treatment-Related Cardiotoxicity Risk Prediction for Breast Cancer Patients with a Multimodal AI-based System$642,454
R01 · FY2025 · CA
Therapeutic Strategies to Mitigate Toxicities of Anthracycline-Based Therapeutics$730,587
R01 · FY2024 · HL
Novel patient biomarkers and mechanisms of TKI associated Cardiotoxicity$688,364
R01 · FY2024 · HL · contact PI
Early Detection and Mechanisms of Cancer Immunotherapy Associated Cardiotoxicity$165,672
K23 · FY2024 · HL · contact PI
Novel patient biomarkers and mechanisms of TKI associated Cardiotoxicity$637,883
R01 · FY2023 · HL · contact PI
Early Detection and Mechanisms of Cancer Immunotherapy Associated Cardiotoxicity$165,672
K23 · FY2023 · HL · contact PI
Early Detection and Mechanisms of Cancer Immunotherapy Associated Cardiotoxicity$165,672
K23 · FY2022 · HL · contact PI
Early Detection and Mechanisms of Cancer Immunotherapy Associated Cardiotoxicity$165,672
K23 · FY2021 · HL · contact PI